We use a unique science-driven approach to engineer endolysins and antimicrobial vectors into targeted antibacterial treatments, leveraging the high potential of both technologies for our proprietary products.
We create endolysins optimized for specific and effective treatments using advanced molecular engineering techniques. Our molecules selectively target harmful bacteria – including resistant strains – which cause and exacerbate acute and chronic illnesses. The natural bacteria of the microbiome, beneficial for our health, remain unaffected. Due to the unique mode of action of endolysins, the emergence of resistance is extremely unlikely.
Our engineered antimicrobial vector technology is leveraging the genetic scaffold of bacteriophages to engineer novel and patentable precision antimicrobials as a new class of biologics for the treatment of bacterial infections.
Our state-of-the art Drug Discovery unit for endolysins and antimicrobial vectors is based in Zurich, Switzerland.
Micreos is bringing engineered endolysin-based treatments to patients suffering from diseases that are caused or aggravated by pathogenic bacteria. This approach is currently being applied to two therapeutic areas: Cutaneous T-cell Lymphoma (CTCL) and Atopic Dermatitis (AD)
Colonization of the skin with Staphylococcus aureus (S. aureus) has a dual effect on patients with cutaneous T-cell lymphoma (CTCL) contributing to skin symptoms and also proliferation of malignant T-cells and disease progression.
CTCL has a profound impact on patients’ quality of life due to its chronic nature and the fact that a considerable proportion of patients have no response or no sustainable response to current treatments.
Our clinical development of MEndoC aims to give CTCL patients a treatment option with a completely new mode of action compared to existing therapies. MEndoC:
We anticipate its use as a topical treatment of the inflammatory skin symptoms associated with CTCL and for the reduction of disease activity and tumor load in adult patients with CTCL.
Prevalence of this incurable, orphan malignancy in the US in 2022 is estimated to be 64,690.
We welcome collaboration with partners who share our ambition, please contact Natalie Samuel:
contact@micreos.com
Colonization of the skin with Staphylococcus aureus (S. aureus) in people with Atopic Dermatitis (AD) plays a significant role in the pathophysiology and severity of the condition. S. aureus produces virulence factors which contribute towards inflammation, skin barrier dysfunction, pruritus, and increased risk of infection.
Due to the chronic nature of the disease AD has a significant long-term impact on quality of life of patients in health-related aspects such as physical, psychosocial, and mental functioning. This means it is imperative to have treatments which are well tolerated and can be used long-term.
MEndoA is first-in-class with a completely new mode of action to existing therapies. Through our clinical development of MEndoA, we want to give all AD patients a treatment option which:
MEndoA has the potential to be used across the treatment paradigm – for treatment of flares and as maintenance to prevent flares – in people with mild, moderate or severe AD.
In a meta-analysis, the pooled prevalence of S. aureus colonization among patients was 70% for lesional skin.
We welcome collaboration with partners who share our ambition, please contact Natalie Samuel:
contact@micreos.com